Intershunt
Fridley, US · Founded 2015 · 11 employees on LinkedIn · 1 known investors
Intershunt develops the Dynama System (also known as the PAS-C System), an investigational interatrial shunting device designed to create a pathway in the heart's upper chambers to reduce elevated left atrial pressure and relieve heart failure symptoms. It targets select heart failure patients with reduced ejection fraction and is being evaluated in the EASE HF2 early feasibility clinical study.
Founders & leadership
HL
Harlan Lee SorkinExecutive
GM
Gil M. VardiNamed on SEC filing
Board
DH
Denis HarringtonBoard director
DA
David AdairBoard director
JB
Jim BullockBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$27.4M disclosed across 3 rounds · 2020–2024
▶$23.4MraisedSep 2024 · 35 investors · Other Health CareRule 506(b)
▶$23.4MraisedSep 2024 · 35 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Denis HarringtonDirector
- Gil M. VardiDirector
- David AdairDirector
- Jim BullockDirector
- Harlan Lee SorkinExecutive Officer, Director
- Offering amount
- $30.4M
- Amount sold
- $23.4M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$885.7KraisedDec 2021 · 13 investors · Other Health CareRule 506(b)
▶$885.7KraisedDec 2021 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James BullockDirector
- Denis HarringtonDirector
- Gil M. VardiDirector
- Harlan L. SorkinExecutive Officer, Director
- David AdairDirector
- Offering amount
- $3.5M
- Amount sold
- $885.7K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.1MraisedJan 2021 · 28 investors · Other Health CareRule 506(b)
▶$3.1MraisedJan 2021 · 28 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Gil M. VardiDirector
- Harian Lee SorkinExecutive Officer, Director
- Offering amount
- $3.6M
- Amount sold
- $3.1M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Rf Surgical4 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Vumedi4 shared keywordsVumedi operates a peer-to-peer video education platform where clinicians watch lectures and technique videos across dozens of medical specialties. It partners with academic institutions, hospitals, and life sciences companies to provide continuing medical education content to doctors.
Companies competing with Intershunt for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Intershunt do?
- Intershunt develops the Dynama System (also known as the PAS-C System), an investigational interatrial shunting device designed to create a pathway in the heart's upper chambers to reduce elevated left atrial pressure and relieve heart failure symptoms. It targets select heart failure patients with reduced ejection fraction and is being evaluated in the EASE HF2 early feasibility clinical study.
- Who are Intershunt's investors?
- Intershunt's investors include Solas BioVentures.
- How much funding has Intershunt raised?
- Intershunt has disclosed $27.4M raised across 3 rounds.
- Where is Intershunt headquartered?
- Intershunt is headquartered in Fridley, US.